ZVRA250117P2000
- 0.00
- 0.000.00%
Zevra Therapeutics Newsroom
Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More
Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Zevra Therapeutics Restructures to Focus on Rare Diseases
Zevra Therapeutics Announces Departure of CDO Christal Mickle, CSO Sven Guenther
Express News | Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co
Express News | Zevra Therapeutics Inc - Zevra Has Discontinued Its in-House Drug Discovery Activities
Express News | Zevra Therapeutics Inc - to Close Laboratory Facilities in Iowa and Virginia
Express News | Zevra Therapeutics Inc - Eliminates Positions in Chemistry, Manufacturing and Controls and Clinical Development
Express News | Zevra Therapeutics Inc - Consolidates Development and Scientific Functions Under Cmo Adrian Quartel
Press Release: Zevra Therapeutics Announces Organizational Changes
Express News | Zevra Therapeutics Announces Organizational Changes
Zevra Therapeutics to Participate at Upcoming Investor Conferences
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Zevra Therapeutics Announces Availability of MIPLYFFA, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssist Patient Support Program
Express News | Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report